DB-102- Emerging Insight and Market Forecast-2030

DB-102- Emerging Insight and Market Forecast-2030

  • February 2021 •
  • 50 pages •
  • Report ID: 6020297 •
  • Format: PDF
“DB-102- Emerging Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Diffuse large B cell lymphoma in 7 Major Markets. A detailed picture of the DB-102 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020–2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview
DB102 (enzastaurin) is an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor of the PKC beta, PI3K, and AKT pathways that has been studied in more than 3,000 patients across a range of solid and hematological tumor types. DB102 was originally developed by Eli Lilly and for which Denovo has acquired worldwide rights. DB102 received orphan drug designation in DLBCL and glioblastoma multiforme (GBM) from the FDA and EMA.
DB102 is the world’s first oral small-molecule kinase inhibitor targeting PKC-?. A retrospective analysis found that it has significant curative effects in high-risk DLBCL patients who are DGM1 positive.

Scope of the report
The report provides insights into:
• A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
• Elaborated details on regulatory milestones and other development activities have been provided in this report.
• The report also highlights the drug research and development activity details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around DB-102.
• The report contains forecasted sales for DB-102 till 2030.
• Comprehensive coverage of the late-stage emerging therapies (Phase III) for Diffuse large B cell lymphoma.
• The report also features the SWOT analysis with analyst insights and key findings of DB-102.

Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

DB-102 Analytical Perspective
• In-depth DB-102 Market Assessment
This report provides a detailed market assessment of DB-102 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

• DB-102 Clinical Assessment
The report provides the clinical trials information of DB-102 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights
• In the coming years, the market scenario for Diffuse large B cell lymphoma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence DB-102 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Other emerging products for Diffuse large B cell lymphoma are giving market competition to DB-102 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of DB-102.
• Our in-depth analysis of the forecasted sales data of DB-102 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DB-102.

Key Questions
• Which company is developing DB-102 along with the phase of the clinical study?
• What is the technology utilized in the development of DB-102?
• What is the product type, route of administration and mechanism of action of DB-102?
• What is the clinical trial status of the study and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DB-102 development?
• What are the key designations that have been granted to DB-102?
• What is the forecasted market scenario of DB-102?
• What is the history of DB-102 and what is its future?
• What is the forecasted sales of DB-102 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how these are giving competition to DB-102?
• Which are the late-stage emerging therapies under development for the treatment of the Diffuse large B cell lymphoma?